Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17624329 | 0.84 | CYP2D6 (0.34) | HSD17B10 | |
| SCHEMBL25044367 | 0.84 | HSD17B10 (0.35) | HSD17B10 | |
| SCHEMBL17624421 | 0.82 | KDM1A (0.33) | KDM1AHSD17B10 | |
| SCHEMBL25044369 | 0.81 | HSD17B10 (0.39) | HSD17B10 | |
| SCHEMBL24940878 | 0.81 | CYP2D6 (0.37) | HSD17B10 | |
| SCHEMBL17624449 | 0.81 | CYP3A4 (0.39) | — | |
| SCHEMBL24673400 | 0.79 | CYP2D6 (0.38) | HSD17B10 | |
| SCHEMBL26450862 | 0.78 | HSD17B10 (0.31) | HSD17B10 | |
| SCHEMBL25094270 | 0.77 | — | — | |
| SCHEMBL25004749 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11912708-B2 | Macrocyclic heterocycles and uses thereof | KUMQUAT BIOSCIENCES INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-11912708-B2 | Macrocyclic heterocycles and uses thereof | KUMQUAT BIOSCIENCES INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-20170305922-A1 | CARM1 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2017-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11912708-B2 | Macrocyclic heterocycles and uses thereof | HRAS, KRAS, TP53 | KDM1A 4613/4885HSD17B10 3312/4885 |
| US-20170305922-A1 | CARM1 INHIBITORS AND USES THEREOF | CARM1, ADRM1, PRMT1 | KDM1A 362/4885HSD17B10 2910/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.